2022 Revenues ($USD) : $2,484,522,942
2022 Revenues (foreign currencies) : JP¥272,900,000,000
2022 R&D spend : $66,460,306
2022 Number of Employees : n/a
Fiscal Year End : 3/31/2022
Company CEO : Shigekazu Takeuchi, president and CEO

The Japan-based company focuses on lab testing, related services and in vitro diagnostics. HU Group has been seeking to promote the digitization of testing information — and using data to create a medical/health information platform. –CN